SecBot SecBot

PBM

PSYENCE BIOMEDICAL LTD.
Nasdaq· Pharmaceutical Preparations· Inc. A6· CIK 0001985062 Biotech & Drug Discovery
$4.07 −0.09 (−2.16%)
Oct 26 4:00 PM ET · prev $4.16
Market cap
$21.9M
Nano cap
1 year
−96.8%
from $127.34 · Oct 27
30 days
−28.1%
from $5.66
52-week range
$2.23–129.69
−97% from high · low Feb 23
Avg volume 20D
40.7K
Oct 5 spike 142.3K
Short interest
26.8K
≈0.7% of shares · −44.3%
Days to cover
1.0
at average volume
Filing reports
10
analyzed by SecBot
SecBot read MIXED 11 reports · 90 days
Balance 1 bearish · 0 bullish · 1 mixed · 9 neutral oldest → newest, height = score
Avg score ·High conf. 4/11
Strongest MIXED Psyence Biomedical completed its backstop investment of $2.6 million in PsyLabs after both ibogaine…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersCOVERING

    Short interest −44.3% to 26.8K shares. 1.0 days to cover, ≈0.7% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F
Top holderSharesValue
MORGAN STANLEY37,804$115.7K
JANE STREET GROUP, LLC30,431$93.1K
CITADEL ADVISORS LLC11,693$35.8K
UBS Group AG60$184.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Psyence Biomedical completed its backstop investment of $2.6 million in PsyLabs after both ibogaine milestones were…
6-K — Impact 5/10
Oct 15, 2026 SEC
Psyence Labs Ltd. filed Amendment No. 1 to its Schedule 13D, reporting the acquisition of 1,497,500 common shares of…
SC 13D/A — Impact 5/10
Oct 5, 2026 SEC
AdvisorShares Trust disclosed a 6.78% passive stake in Psyence Biomedical Ltd. via a new Schedule 13G filing, holding…
SC 13G — Impact 3/10
Oct 5, 2026 Press
Psyence BioMed's Texas subsidiary, TIRC, signed a manufacturing services agreement with DEA-registered Benuvia…
Impact 4/10
Oct 5, 2026 Contract
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade iboga
Sep 28, 2026 Press
Psyence Biomedical subsidiary Texas Ibogaine Research Corporation (TIRC) signed a binding term sheet with…
Impact 4/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
26,839
shares short
-44.3%
vs prior settlement
1.0
days to cover
≈0.7%
of shares outstanding
Trading halts
Aug 18, 2026Volatility PauseResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 5, 2026
Contract
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S…
Sep 28, 2026
M&A
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to…
Aug 18, 2026
Trading halt
Halt Resumed: PBM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-18T16:58:02.000Z | Resumed 2026-08-18T17:18:03.000Z
Aug 18, 2026
Trading halt
Trading Halt: PBM — LUDP (Volatility Trading Pause)
Psyence Biomedical Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
May 15, 2026
Press release
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company…

SecBot reports

10 filings · 4 press releases · 0 bullish · 2 bearish · 1 mixed · 7 neutral
All PBM filing & press-release reports (14)